Clinical reports indicate that the objective response rate (ORR) of trastuzumab in HER2-positive gastric cancer was lower than that of HER2-positive breast cancer (about 16 % vs. 26 %) [2, 4]. This evidence concerns the gene ERBB2 and gastric cancer.